当前位置:首页 - 行情中心 - 川宁生物(301301) - 财务分析 - 现金流量表

川宁生物

(301301)

  

流通市值:51.39亿  总市值:185.28亿
流通股本:6.19亿   总股本:22.32亿

现金流量表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金1,816,019,158.89577,902,889.733,372,852,789.692,759,760,332.74
  收到的税费返还56,928,758.181,610,619.57,752,108.422,932,581.56
  收到其他与经营活动有关的现金33,297,408.2418,380,743.11106,323,178.8164,561,162.12
  经营活动现金流入小计1,906,245,325.31597,894,252.343,486,928,076.922,827,254,076.42
  购买商品、接受劳务支付的现金636,200,658.98155,293,761.151,834,727,762.281,397,070,411.12
  支付给职工以及为职工支付的现金279,961,228.87168,207,053.62497,582,852.28371,438,880.45
  支付的各项税费203,415,721.2885,067,170.75524,858,829.31462,680,179.51
  支付其他与经营活动有关的现金11,314,881.426,645,330.8780,699,154.7225,123,340.03
  经营活动现金流出小计1,130,892,490.55415,213,316.392,937,868,598.592,256,312,811.11
  经营活动产生的现金流量净额775,352,834.76182,680,935.95549,059,478.33570,941,265.31
二、投资活动产生的现金流量:
  收回投资收到的现金770,801,434.09550,606,794.642,791,038,607.771,920,903,734.05
  取得投资收益收到的现金99,040-01,126,793.43
  处置固定资产、无形资产和其他长期资产收回的现金净额--154.87-
  投资活动现金流入小计770,900,474.09550,606,794.642,791,038,762.641,922,030,527.48
  购建固定资产、无形资产和其他长期资产支付的现金29,894,314.4317,049,007.7197,211,603.862,973,255.67
  投资支付的现金993,000,000603,000,0002,925,759,277.782,161,029,277.78
  支付其他与投资活动有关的现金-6,830--
  投资活动现金流出小计1,022,894,314.43620,055,837.713,022,970,881.582,224,002,533.45
  投资活动产生的现金流量净额-251,993,840.34-69,449,043.07-231,932,118.94-301,972,005.97
三、筹资活动产生的现金流量:
  吸收投资收到的现金8,787,398.4-20,135,52020,135,520
  其中:子公司吸收少数股东投资收到的现金--7,200,0007,200,000
  取得借款收到的现金399,981,132.08200,000,000747,990,436.81499,989,863.01
  筹资活动现金流入小计408,768,530.48200,000,000768,125,956.81520,125,383.01
  偿还债务支付的现金358,000,000346,000,000817,333,333510,333,333
  分配股利、利润或偿付利息支付的现金395,775,999.25,937,913.05622,104,954.13618,269,188.56
  支付其他与筹资活动有关的现金32,456,944.826,879,329.62,603,515.2577,615.2
  筹资活动现金流出小计786,232,944378,817,242.651,442,041,802.331,129,180,136.76
  筹资活动产生的现金流量净额-377,464,413.52-178,817,242.65-673,915,845.52-609,054,753.75
四、汇率变动对现金及现金等价物的影响-4,577,612.08-5,105,726.252,670,112.452,265,910.67
五、现金及现金等价物净增加额141,316,968.82-70,691,076.02-354,118,373.68-337,819,583.74
  加:期初现金及现金等价物余额734,213,300.93734,213,300.931,088,331,674.611,085,404,379.06
  期末现金及现金等价物余额875,530,269.75663,522,224.91734,213,300.93747,584,795.32
补充资料:
  净利润274,081,202.28-768,346,157.39-
  资产减值准备9,788,239.55-27,737,334.93-
  固定资产和投资性房地产折旧283,371,510.19-552,923,990.02-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧283,371,510.19-552,923,990.02-
  无形资产摊销10,069,815.15-19,627,677.52-
  长期待摊费用摊销439,126.5-878,253.01-
  处置固定资产、无形资产和其他长期资产的损失---345,957.83-
  固定资产报废损失715,672.38-1,390,522.65-
  公允价值变动损失217,381.95-1,483,217.89-
  财务费用22,900,274.53-40,474,674.98-
  投资损失1,401,695.02-2,071,203.43-
  递延所得税1,600,120.64--922,003.27-
  其中:递延所得税资产减少1,600,120.64--922,003.27-
  存货的减少89,944,221.9--182,286,435.89-
  经营性应收项目的减少75,073,317.93--527,477,968.93-
  经营性应付项目的增加-2,718,810.68--162,487,727.15-
  其他---7,297,177.5-
  不涉及现金收支的投资和筹资活动金额其他项目--10,162,374.09-
  现金的期末余额875,530,269.75-734,213,300.93-
  减:现金的期初余额734,213,300.93-1,088,331,674.61-
  现金及现金等价物的净增加额141,316,968.82--354,118,373.68-
公告日期2026-08-252026-04-232026-03-312025-10-28
审计意见(境内)标准无保留意见
TOP↑